To demonstrate that intratumoral CD8 T-cell infiltration after combination therapy of regorafenib with anti-PD1 antibody was mediated by CXCL10/CXCR3 axis, we next evaluated the effects of combined regorafenib (10 mg/kg)/anti-PD1 antibody therapy on RIL-175 HCC growing in Cxcr3-deficient (Cxcr3–/–) versus Cxcr3-proficient (Cxcr3+/+) C57Bl/6 mice. The gene discussed is CD8A; the disease is hepatocellular carcinoma.